PTGS2 and cancer: It is well established that several types of cancer overexpress cyclooxygenase-2 (COX-2) and cyclooxygenase-1 (COX-1), which has driven the use of non-steroidal anti-inflammatory drugs (NSAIDs) in oncology [12].